Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 9/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2980034 | 0.85 | CYP2A6 (0.43) | CYP2A6ERN1KDM4ERAB9AMEN1 | |
| SCHEMBL16048730 | 0.78 | CA1 (0.46) | KDM4EMEN1KMT2ACTSLTYR | |
| SCHEMBL16048732 | 0.78 | CA1 (0.46) | KDM4EMEN1KMT2ACTSLTYR | |
| SCHEMBL24339585 | 0.77 | CYP2A6 (0.47) | CYP2A6KDM4ERAB9AMEN1NPC1 | |
| SCHEMBL21625588 | 0.77 | CYP2A6 (0.47) | CYP2A6MEN1KMT2A | |
| SCHEMBL11661739 | 0.77 | IDO1 (0.39) | IDO1 | |
| SCHEMBL5154238 | 0.76 | CYP2A6 (0.40) | CYP2A6ERN1PTGS2 | |
| SCHEMBL16077423 | 0.70 | TTR (0.50) | CTSL | |
| SCHEMBL22122313 | 0.69 | IDO1 (0.33) | IDO1 | |
| SCHEMBL911722 | 0.69 | NEK1 (0.33) | KDM4EIDO1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114437582-A | Environment-friendly energy-saving ink cleaning agent and preparation method thereof | 南通漫游通艺术包装有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-112457303-B | Fluorescent compound and preparation method and application thereof | 浙江海洋大学 | 2022-01-07 | — | — | CN | claimed |
| CN-112666143-A | Fluorescence detection method for alkaline phosphatase activity of environment | 浙江海洋大学 | 2021-04-16 | — | — | CN | claimed |
| CN-112457303-A | Fluorescent compound and preparation method and application thereof | 浙江海洋大学 | 2021-03-09 | — | — | CN | claimed |
| EP-4665716-A1 | CRYSTALLINE FORMS OR SALTS OF A DEUTERATED COMPOUND | ALEBUND PHARMACEUTICALS (HONG KONG) LIMITED (HK) | 2025-12-24 | — | — | EP | disclosed |
| CN-118480034-B | Crystalline forms or salts of deuterated compounds | 礼邦医药(香港)有限公司 | 2025-02-11 | — | — | CN | disclosed |
| WO-2024169698-A1 | CRYSTALLINE FORMS OR SALTS OF A DEUTERATED COMPOUND | ALEBUND PHARMACEUTICALS (HONG KONG) LIMITED (CN) | 2024-08-22 | — | — | WO | disclosed |
| US-20240270731-A1 | DEUTERATED COMPOUNDS | ALEBUND PHARMACEUTICALS (HONG KONG) LIMITED (CN) | 2024-08-15 | — | — | US | disclosed |
| CN-118480034-A | Crystalline forms or salts of deuterated compounds | 礼邦医药(香港)有限公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4384507-A1 | DEUTERATED COMPOUNDS | ALEBUND PHARMACEUTICALS (HONG KONG) LIMITED (HK) | 2024-06-19 | — | — | EP | disclosed |
| CN-116848095-B | Deuterated compounds | 礼邦生物医药(江苏)有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024005460-A1 | COMPOUND COMPRISING SELF-IMMOLATIVE GROUP AND LIGAND-DRUG CONJUGATE COMPRISING SAME | 주식회사 트리오어 | 2024-01-04 | — | — | WO | disclosed |
| WO-2004041275-A1 | SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004020420-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-03-11 | — | — | WO | disclosed |
| EP-1392295-A1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| US-6642389-B2 | For therapy of diabetes | HOFFMANN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030055265-A1 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. | 2003-03-20 | — | — | US | disclosed |
| WO-2002092084-A1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-21 | — | — | WO | disclosed |
| WO-1998042691-A1 | NEW THIAZOLEDINEDIONES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THE SAME | ROCHE DIAGNOSTICS GMBH (DE) | 1998-10-01 | — | — | WO | disclosed |
| WO-1997043284-A1 | NEW THIAZOLIDINEDIONES, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS CONTAINING THE SAME | BOEHRINGER MANNHEIM GMBH (DE) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270731-A1 | DEUTERATED COMPOUNDS | CYP2D6, CYP11B2, DHCR7 | CYP2A6 67/4885ERN1 3833/4885KDM4E 4082/4885 |
| US-20030055265-A1 | Oxazole derivatives | PPARD, PPARA, PPARG | CYP2A6 1435/4885ERN1 2314/4885KDM4E 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.